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Introduction. A burgeoning number of systematic reviews considering lurasidone in the treatment of bipolar depression have
occurred since its Food and Drug Administration extended approval in 2013. While a paucity of available quantitative evidence
still precludes preliminary meta-analysis on the matter, the present quality assessment of systematic review of systematic reviews,
nonetheless, aims at highlighting current essential information on the topic.Methods. Both published and unpublished systematic
reviews about lurasidone mono- or adjunctive therapy in the treatment of bipolar depression were searched by two independent
authors inquiring PubMed/Cochrane/Embase/Scopus from inception until October 2016. Results. Twelve included systematic
reviews were ofmoderate-to-high quality and consistent in covering the handful of RCTs available to date, suggesting the promising
efficacy, safety, and tolerability profile of lurasidone. Concordance on the drug profile seems to be corroborated by a steadily
increasing number of convergent qualitative reports on the matter. Limitations. Publication, sponsorship, language, citation, and
measurement biases. Conclusions. Despite being preliminary in nature, this overview stipulates the effectiveness of lurasidone in
the acute treatment of Type I bipolar depression overall. As outlined bymost of the reviewed evidence, recommendations for future
research should include further controlled trials of extended duration.
1. Introduction
Although the Diagnostic and Statistical Manual for Mental
Disorders-Fourth Edition (DSM-IV) [1] poses mania as the
hallmark of bipolar disorder (BD), depression is often the
most enduring facet of the illness as emphasized by the Fifth
edition of the Manual [2] requiring significant treatment
efforts [3]. Yet, only a handful of randomized clinical trials
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(RCTs) exist about bipolar depression in comparison to
major depressive disorder (MDD), which may be because
unipolar “endogenous” or “melancholic” major depression
episodes (MDEs) have long been considered equivalent to
bipolar MDEs, from clinical, neurobiological, and treatment-
modality standpoints [4]. Regrettably, the only reservation
was that antidepressants might switch to the manic pole; thus
the enduring common clinical practice among clinicians was
to seamlessly transpose the clinical data andwisdom from the
treatment of unipolar to bipolar depression [5].
This later misconception has long been corroborated by
anecdotal reports suggesting that most clinicians may still
perceive medications as belonging to a class with regard to
a specific therapeutic action rather than based on aimed
“neuroscience-nomenclature” approach grounded on the
pharmacological profile of the drug [6], both in the specialty
and in general practice settings accessed by patients with BD
[7]. Yet, therapeutic “class effect” in BD is an exception rather
than rule [8].
The majority of patients with bipolar depression fail to
respond adequately to pharmacotherapy [9], whereas the use
of standard antidepressant medications, even when associ-
ated with established mood-stabilizers, poses major efficacy
concerns beyond overall short- and long-term tolerability
issues, especially for Type I BD (BD-I) and/or in the presence
of associated mixed and/or atypical features, just to mention
few [10, 11].
In contrast, evidence in support of the use of at least some
of the second-generation antipsychotic (SGA)mono- or add-
on therapy either for MDD [12, 13] or bipolar depression [14–
18] is increasing over the time, though additional safe and
effective Food and Drug Administration- (FDA-) approved
SGAs for bipolar depression are solicited [19].
Currently, olanzapine-fluoxetine combination (OFC),
quetiapine (either the standard or the extended release
preparation), and lurasidone are the only FDA drugs granted
(extended) approval for the (acute) treatment of bipolar
depression in adults [20, 21].
Lurasidone received FDA approval for the treatment of
schizophrenia in adults in October 2010 and was granted
extended approval on June 2013 for the treatment of acute
depression associated with BD-I in adults [22], either as
monotherapy [23] or as adjunctive treatment to either lithium
or valproate [24] flexible-dose regimen trials, further assessed
in subsequent retrospective/prospective data analysis [25].
Potential safety (namely, the risk to the subject/patient,
usually assessed in by laboratory testing [e.g., clinical chem-
istry and hematology], physical examination [vital signs],
clinical adverse event[s], AEs, and other tests, e.g., the electro-
cardiogram), tolerability (namely, the degree to which overt
AEs can be tolerated by the subject/patient), and effectiveness
(usually, “effectiveness” trials [pragmatic trials] measure the
degree of beneficial effect under “real world” clinical set-
tings rather than the “efficacy” tested by “explanatory” trials
aiming at determining whether an intervention produces
the expected result under ideal circumstances) of adjunctive
lurasidone across a broad range of treatment resistant BD
outpatients otherwise excluded by routine clinical trials (e.g.,
those with mixed and/or rapid-cycling features; those taking
additional psychiatric or nonpsychiatric medications; and/or
older-age cases of BD) have been preliminarily postulated
[26–29] though critically appraised by independent authors
[30].
While the overall effect size of OFC, quetiapine (regard-
less of release formulation), and lurasidone in mitigating
depressive symptoms is similar, the later one showed a
lower propensity for weight gain as well as overall metabolic
neutrality in the bipolar population [20, 21].
Lurasidone, compared to previous FDA-approved SGAs
for bipolar depression, yielded comparable benefits (all had
single-digit number needed [NNT] for treatment versus
placebo response or remission) and less risk of harm (double-
digit or greater numbers needed to harm [NNH] with
lurasidone compared to single-digit NNHs for sedation
with quetiapine and for ≥7% weight gain with olanzapine-
fluoxetine combination) and thus a substantially more favor-
able likelihood to be helped or harmed [LHH] (> or≫1) with
lurasidone monotherapy and adjunctive therapy, compared
to quetiapine and olanzapine-fluoxetine combination (LHH
< or ∼1) [31]. NNT, NNH, and LHH represent widely
well-recognized indexes most clinicians are progressively
becoming familiar with [32]. Nonetheless, the overall clinical
validity and generalizability of these later indexes have been
seldom questioned by some [33].
A burgeoning number of systematic reviews have
nonetheless occurred since the pivotal RCTs leading to
FDA extended approval of lurasidone, as the need for better
efficacy/tolerability profile drugs for bipolar depression
still represents a priority for the prescribing clinicians,
policy-makers, and the suffering ones, indeed.
More recently, calls have been made for updated brief
reviews to provide decision-makers with the essential evi-
dence they need in a shorter time frame, but the possible
limitations of such brief reviews, compared to full-systematic
reviews, require further methodological research [34].
In recent years, however, decision-makers who were
once overwhelmed by the number of individual studies have
become faced by a plethora of reviews [35, 36]. This is
compelling, especially when novel compounds of potential
priority interest for the clinical practice like lurasidone, even
in the treatment of BD,may need to await for additional RCTs
to allow reliable meta-analytic pooling [37, 38].
Therefore, while awaiting for additional primary research
trials to allow reliable and large-scale quantitative extrac-
tions, varying approaches have been proposed [39] to pro-
mote quality assessment of systematic reviews of system-
atic reviews (or overviews) to be eventually accounted for
subsequent umbrella reviews (broad coverage of systematic
reviews and meta-analyses) [40]. Among others, several
approaches including the Preferred Reporting Items for Sys-
tematic review andMeta-Analysis-Protocols, PRISMA-P [41]
(formerly, PRISMA,QUOROM), or organizations devoted to
the preparation of systematic reviews, including the National
Institute of Health and Clinical Excellence (NICE) in the UK,
the Evidence-based Practice Centre Program in the US, the
Joanna Briggs Institute, and the International Campbell and
Cochrane Collaborations arose [39]. It was not until 2009
that “A Measurement Tool to Assess Systematic Reviews”
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Table 1: Search strategy across alternative databases (queries run on October 14, 2016).
Set Medline (via PubMed)
1 #1 Lurasidone Hydrochloride [MeSHMajor Topic]∗
2 #2 review[Publication Type] OR meta-analysis[Publication Type]
3 Sets 1-2 were combined with “OR”
4 Bipolar disorder
5 Depression
6 Sets 1–5 were combined with “OR” & “AND”
Most permissive (generic PubMed - no
MeSH headings) ((Lurasidone) AND Bipolar) AND review[Publication Type]
Embase
Most permissive #1 “lurasidone”/exp OR lurasidone AND “bipolar depression”:ab,tiAND review:it
Scopus
Most permissive (TITLE-ABS-KEY (lurasidone) AND TITLE-ABS-KEY (bipolardisorder)) AND DOCTYPE (re)
Cochrane Library
Most permissive “Lurasidone in Title, Abstract, Keywords and ‘bipolar disorder’ inTitle, Abstract, Keywords and ‘review’ in Publication Type ”
Note. Words written in italic were used as MeSH headings; the others were used as free text.
∗Proposed entry terms, then accounted as free text integrations:
Hydrochloride, Lurasidone
Lurasidone HCl
HCl, Lurasidone
SM 13496
13496, SM
SM13496
SM-13496
SM-13,496
SM 13,496
SM13,496
Lurasidone
N-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinylmethyl)-1-cyclohexylmethyl)-2,3 bicyclo(2.2.1)heptanedicarboximide
Latuda.
(AMSTAR) was documented [42], proving to be a potentially
reliable and valid assessment tool to specifically evaluate the
methodological quality of systematic reviews [43].
Therefore, the aim of the present overview was to assess
the methodological quality of systematic reviews assessing
the evidence about lurasidone in the treatment of bipolar
depression, with the ultimate goals of (i) ranking and priori-
tizing those reviews for which the methodology would allow
reliable conclusions and recommendations for the future
needs; (ii) critically pointing out which unmet needs and
expectations have been highlighted by the clinician authors
to be implemented by future lines of research about the
pharmacological treatment of acute bipolar depression in
adults with a special emphasis towards lurasidone, prompting
for attention by policy and clinical decision-makers.
2. Materials and Procedures
Overall methods and procedures resemble those adopted by
recent peer-review articles involving the use of AMSTAR
methodology [42, 43], as applied to heterogeneous medical
fields of research [45].
2.1. Search Strategy for the Identification of Systematic Reviews.
A protocol was drafted before the implementation of the
review (a copy is available from the authors). Searches
were conducted of Medline (via PubMed), EMBASE and
the Cochrane library (which includes the DARE database
of abstracts of reviews on interventions), and Scopus, on
October 14, 2016, and included a combination of free text and
MeSH terms (please refer to Table 1). Despite the relatively
recent introduction of lurasidone, indexes were searched
from inception aiming at gathering as much information as
possible on the topic. Searches were limited to “systematic
reviews” or “review” type publication across varying sources.
No language restrictionswere imposed although only English
language results were retained.This strategy was purportedly
performed to get a better insight about any eventual language
and regional publication differential trend on the topic. The
title and abstract of each article were scanned (independently
by two reviewers: MF and LO) and full-reprints of articles of
potentially eligible reviews were obtained. Potentially eligible
reviews were then screened, again independently by two
reviewers, per the review selection criteria outlined below. All
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resulting references were further screened for identification
of additional reviews.
2.2. Review Selection Criteria. Only systematic reviews were
included. Case reports, controlled RCT (which were not
part of a review), were excluded. Those narrative reviews
indexed by major databases as “systematic” were nonetheless
identified and then anyway screened for eventual inclusion
and overall assessment. Both systematic reviews of RCTs
and observational studies were eligible for inclusion. To
be considered for inclusion, the review had to include
evidence about the use of lurasidone (any dose) for bipolar
disorder (any mood polarity), either for the acute or for
the maintenance mono- or adjunctive treatment therapy.
Systematic reviews covering drugs other than lurasidone
or any additional non-BD prescription of lurasidone were
likewise included in the present overview. Populations at
interest were therefore “BD patients exposed to lurasidone.”
2.3. Preliminary Data Abstraction. For each review meeting
the inclusion criteria data were abstracted independently by
two reviewers (MF and DDB). All data was compared and
identified anomalies rectified by mutual agreement. Data
were obtained exclusively from the systematic reviews, while
additionalmanual screeningwas planned to enrich the search
strategy. The primary study reports were likewise reviewed
before assessment of systematic review reporting on the
matter. Data abstracted from each systematic review included
(i) authors and date of publication; country of origin (leading
author most current affiliation); major biases, including
sponsorship bias. In case of reviews covering multiple RCT
studies, these later ones were punctually referenced in Table 2
(please see the text for results).
2.4. Assessment of Data Quality. The methodological qual-
ity and risk of bias of the systematic reviews at interest
were performed using the AMSTAR items [42, 43] by two
independent reviewers (MF and DDB). Risk of bias of
primary studies was not assessed where this was covered
by the corresponding systematic reviews. However, we did
not record whether and how the reviews had assessed the
quality of the primary studies and which method had been
used (for example the Cochrane risk of bias tool) [54].
Briefly, the AMSTAR is a tool aiming at addressing relevant
domains (as applicable): establishing the research question
and inclusion criteria before the conduct of the review,
data extraction by at least two independent data extractors,
comprehensive literature review with searching of at least
two databases, key word identification, expert consultation
and limits as necessary, detailed list of included/excluded
studies and consideration of quality assessments in analysis
and conclusions, appropriate assessment of homogeneity,
assessment of publication bias, and a statement of any
conflict of interest. Therefore, (i) the extent of searching
undertaken; (ii) description of review selection and inclusion
criteria; (iii) assessment of publication bias; (iv) assessment
of heterogeneity; and (v) comparability of included reviews
are emphasized by the AMSTARmethod [39]. The AMSTAR
checklist items are presented in the form of questions, with
possible responses of “yes” (item/question fully addressed),
“no” (item/question not addressed), “cannot answer” (not
enough information to answer the question), and “not appli-
cable,” https://amstar.ca/Amstar_Checklist.php; the actual
eleven domains rated by the AMSTAR and its psychometric
features have been further detailed elsewhere [43].
The revised assessment of multiple systematic reviews (R-
AMSTAR) based on appendix 1 included in the open-access
work byKung et al. [44]was nonetheless integrated [55] to the
standard AMSTAR to generate quantitative scores of qualita-
tive evidence [44] since use of the original AMSTAR checklist
alone would have posed subjectivity concerns and possibly
reduced the reliability and replicability of assessments [56].
Specifically, stating the discrepancy existing about standard-
ized scoring of the original AMSTAR domains [55–57],
grading of the R-AMSTAR could vary across different authors
and research themes [55]; we integrated two alternative scores
methods in the assessment of each systematic review: (a) each
of the individual eleven domains of the original instrument
ranged between 1 and 4 (maximum); thus the R-AMSTAR
total scores ranged between 11 (minimum) and 44 (maxi-
mum). Scoring for each domain could be determined based
on the number of satisfied criteria varying across different
domains rather than nonstandardized cut-off scores [44];
(b) based on the later scores values, a percentile ranking is
obtained, for each individual score, which is then translatable
into a letter grade based on the extent of PICO/PIPO research
questions (population, intervention, comparison, prediction,
and outcome) answered, with the following letters: A (best)–E
(worst) range (variable across varying questions). Details
about the domains and proposed scoring of the R-AMSTAR
available in the public domain based on the appendix 1 are
included in the work by Kung and colleagues [44, 55].
2.5. Exclusion of Duplicate Primary Studies (Document in
Systematic Reviews). Both auto- and hand-searches for “type
I” (“duplicates among/across different databases”) and “type
II” (“duplicate publications in different Journals/issues”)
[58] were performed based on Thompson Endnote X7 for
Microsoft Windows.
Reviewswere then screened to exclude systematic reviews
with duplicate primary studies unless they reported on
different outcomes or provided alternative critical account of
the evidence.
2.6. Outcomes. Principal outcomes related to the impressions
and recommendations about efficacy and tolerabilitymade by
the authors given a systematic review at review beyond the
raw data come from the covered original RCTs. Specifically,
overall conclusions drawn by the authors and unmet needs
to be addressed by future studies were included providing a
concise narrative synthesis based on each systematic review
included in the present overview. Conversely, specific out-
comes of treatment interventions reported by the original
RCTs covered across varying reviews were not accounted
herein. On the other side, it is worth mentioning that higher
R-AMSTAR scores and letter grades (e.g., “A”)would indicate
more reliable and trustworthy conclusions.
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Adapted PRISMA-P 2015 Flow Diagram (Moher et al., 2015) for “overview” use
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Figure 1: Flow chart of overview procedures.
3. Results
Stating the lack of quantitative data to abstract (please refer to
Figure 1 for study flow chart) (e.g., treatment effect estimates),
overall synthesis of results could be presented in a narrative
fashion (as outlined in Table 2).
3.1. Overview of the Systematic Evidence. As depicted in
Figure 2 and Table 3, most of the included “systematic”
reviews fell in the upper tier of the quality range according
to the percentile score (or related grade letter): R-AMSTAR
total median score = 27.5 (Interquartile-Range [IQR] = 13),
whereas the range of raw R-AMSTAR scores was equal to
18–36.
On average, only few original RCTs about lurasidone
in the treatment of BD in adults could be “systematically
reviewed” since 2013 (FDA extension of approval beyond
schizophrenia). Moreover, both the pivotal acute mono-
[23] and adjunctive [24] therapy trials were sponsored ones,
as is preliminary data about maintenance [29, 30]. Addi-
tional details about study design, outcomes and measures
of the RCTs consistently covered across the systematically
reviewed reviews or drug development with focus on bipolar
depression [59] could therefore be retrieved in the respective
references provided above.
Table 3
R-AMSTAR total score Frequency Percentile
18.00 1 8.3
19.00 1 16.7
20.00 1 25.0
23.00 1 33.3
24.00 1 41.7
26.00 1 50.0
29.00 1 58.3
30.00 1 66.7
33.00 1 75.0
34.00 1 83.3
36.00 2 100.0
Note. Percentiles ≤ 20.75 would fall in the bottom 25th quartile (grade letter
“D”); percentile range 20.76–27.50 = lower 50th or letter C; percentile range
27.6–33.75 = upper quartile till 75th, or letter B; percentiles ≥ 33.75 would fall
in the top quartile (up to 100th percentile), or letter grade “A.”
3.2. Chemistry. Lurasidone hydrochloride (molecular formu-
la C
28
H
37
ClN
4
O
2
S) is a benzisothiazolinone derivative.
Its molecular weight is 529.14 g/mol. Figure 3 shows
lurasidone chemical structure. Please access https://pubchem
.ncbi.nlm.nih.gov/compound/Lurasidone_HCl#section=Mo-
lecular-Formula for additional details.
BioMed Research International 11
36
33.75
27.5
20.75
18
27.33333333
Quartile distribution
1
11
16
21
26
31
36
41
A
xi
s t
itl
e
Number of included studies = 12;
Median R-AMSTAR total score = 27.5
(IQR = 13). Minimum score = 18; maximum score = 36.
Figure 2: Companion box-plot and quartile distribution for Table 2:
Conversion of raw R-AMSTAR total scores into percentile scores
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Figure 3: 2D conformer of lurasidone (compound: CID 11237860).
Additional reference at https://pubchem.ncbi.nlm.nih.gov/com-
pound/Lurasidone_HCl#section=2D-Structure.
3.3. Essential Pharmacokinetics and Pharmacodynamics Sig-
nature. Substantial consensus exists about the pharmaco-
logical signature of lurasidone hydrochloride across sources
assessing either preclinical or clinical studies on the matter
[60–64], as briefly synthesized below.
3.3.1. Essential Pharmacokinetics of Lurasidone. Lurasidone
is metabolized by the liver via cytochrome (CYP) 3A4 [65]
and it is best absorbed with 350Kcal of food as detailed
elsewhere [66]. Although the requirement to take lurasidone
with food is minimal inconvenience [67], the ability to take it
just once a day is an advance over alternative medications or
polypharmacy regimens [63].
According to the US package insert, rifampin, a potent
CYP3A4-inducer, decreased lurasidone area under the curve
fivefold [68]. There are no published studies of potent
antiepileptic drugs CYP3A4 inducers that are expected to
dramatically increase lurasidonemetabolism, including those
seldom prescribed to BD patients too [69]. Nonetheless, it is
possible that in high doses, oxcarbazepine or topiramate may
influence lurasidone levels [70].
When prescribed as oral monotherapy for depression
associated with BD-I in adults, initial dose should be
20mg/day, with no titration needed and maximum dose
being 120mg/day depending on patient response, tolerability,
and pharmacokinetics issues (in contrast to usually higher
dose range of 80–120mg/day often required for adult cases
of schizophrenia, when used as monotherapy in the absence
of major pharmacokinetic interactions) [61, 71, 72].
3.3.2. Essential Pharmacodynamics of Lurasidone. Lurasi-
done is a full antagonist at dopamine (DA) D2 and serotonin
(or 5-hydroxytryptophan [5-HT]) 2A (5-HT2A) receptors,
with binding affinities (Ki) of 0.47 nanomole (nM) and
0.994 nM, respectively [61, 73]. However, lurasidone also
has high affinity for serotonin 5-HT7 receptors (0.495 nM;
comparable to D2 and 5-HT2A receptors) and has affinity
as partial agonist at 5-HT1A receptors with a Ki of 6.38 nM
[72]. This may be of potential interest because of preclinical
findings of a possible procognitive effect mediated by action
at the serotonin 5-HT7 receptor [60, 61]. Notably, 5-HT7
blockade has been postulated to boost 5-HT1A modulation
by lurasidone antagonism elsewhere postulated as a rein-
forcement of 5-HT1A activity [74]. Lurasidone is also low- to
moderate D3 antagonist [75].
Lurasidone preclinical profile was found predictive of
antipsychotic, antimanic, antidepressant, and procognitive
effects [61], as well as efficacy against negative symptoms of
schizophrenia [63]. Moreover, its lack of affinity for some
receptors (e.g., histamineH1, acetylcholineM1)would predict
improved (metabolic and cognitive) tolerability with respect
to alternative SGAs options approved by the FDA for BD in
adults [61, 63]. Favorable D2/5-HT2A balance would predict
lower propensity for extrapyramidal symptoms [64].
According to the original model proposed by Foun-
toulakis et al. [76], the stronger predictors for antidepres-
sant efficacy in bipolar depression would encompass nore-
pinephrine alpha-1, dopamine (DA)D1, and histamine antag-
onism, followed by 5-HT2A, by muscarinic and dopaminer-
gic D2 andD3 antagonism, and eventually by norepinephrine
reuptake inhibition and 5-HT1A agonist effect [76].
Yet, it is worth noting that the model would therefore
outline a complex interaction between the major neurotrans-
mitter systems without a single target being either necessary
or sufficient to elicit the antidepressant effect in bipolar
depression [76].
While serotonin reuptake inhibition may not play per
se a significant role in bipolar depression [77], it is worth
noticing that norepinephrine activity seems to be of great of
importance [61]. Thus, early bipolar antidepressant activity
excreted by lurasidone has been correlated with disinhibitory
norepinephrinergic effects of agonistic activity at 5-HT1A
(which may play a core mechanism in bipolar depression
[78] beyond major depressive disorder [79]) and antagonism
at alpha-1 norepinephrine and serotonin 5-HT2A receptors,
though the presence of norepinephrine reuptake inhibition
(lurasidone is also weak alpha-2a (autoinhibitory, presynap-
tic) antagonist (Ki = 10.8 nM) for lurasidone [64]) is essential
in order to sustain it [61], whereas dopaminergic activity
overall may likewise play a major role [80].
Finally, while lurasidone pharmacodynamic signature
would represent a good fit of the model proposed by
Fountoulakis et al. (2012) [76], additional peculiar phar-
macodynamics of lurasidone [61], including strong 5-HT7
(and D2) antagonism, otherwise suggestive of procognitive
and mood-enhancing activity possibly via dopamine efflux
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too [81–83], and negligible or null 5-HT3 and 5-HT2C
interactions, otherwise accounted as major potential players
for antidepressant activity in BD [84–86], could not fit the
model, possibly due to lack of additional evidence on the
matter (publication bias) rather than actual negligence of
their neurobiological value on the matter [61].
3.4. Adverse Effects Consistently Documented across Varying
Systematic Reviews Based on Original Studies. An updated
synthesis on major and/or most common AEs with lurasi-
done (even) in the treatment of BD is provided elsewhere
[64]. Briefly, the most commonly reported AEs were nausea,
akathisia, EPS, and sedation. Negligible effects were seen
with respect to changes in fasting glucose, total cholesterol,
low-density lipoprotein cholesterol, prolactin elevation, and
triglycerides’ levels, at least in contrast with alternative SGAs
and/or higher average dose regimens used for schizophrenia
patients [87]. No electrocardiogram abnormalities, not even
significant increase in QT interval length, have been docu-
mented in comparison with placebo or active competitor(s)
from the SGA class. Stating the lack of histamine H1 and
muscarinic M1, as well as strong norepinephrine alpha-1
antagonist, activities, lurasidone has also lower propensity to
induce somnolence compared to most of the available SGA
alternatives [88]. On the contrary, akathisia and dystonia
were important, relatively common, AEs. In addition, it is
worth noting that while the FDA black box warning about
the risk of death in elderly patients with dementia has been
issued as a class black box warning, lurasidone database does
not have studies involving subjects with dementia and has no
reported deaths in clinical trials in this population. Nonethe-
less, we purposely avoided providing quantitative synthesis
of AEs herein as evidence from RCTs studies involving adult
cases of BD is tentative or otherwise hampered by strong
publication bias (and selection bias of included samples),
and cumulative reports derived by some systematic reviews
merged data from schizophrenia cases controlled as well as
noncontrolled reports, with this later cases known to be prone
to higher neurological side effects and being usually exposed
to higher dose of antipsychotic(s) on average [64].
4. Discussion
Theaverage quality of the included systematic reviews ranged
between moderate-to-high scoring, as the mode (“most com-
mon statistical presentation”) was equal to grade letter = “A”
(namely, for 8 out 12 included studies). Overall, concordance
exists about the intriguing efficacy, safety, and tolerability
profile of lurasidone even in the treatment of acute depressive
episodes associated with BD-I, especially when indirectly
compared with other FDA-approved SGAs to date.
This later issue has major implications for the policy-
makers, the clinicians, the patients, and their caregivers,
especially considering that most BD patients require long-
lasting (virtually lifetime enduring) pharmacological treat-
ments (ideally integrated by alternative treatment modal-
ities), thus being particularly vulnerable to many of the
common AEs documented with some of the SGA class com-
pounds already released, especially from cognitive and car-
diometabolic standpoints [89].Thus, there is interest towards
lurasidone as a safer and more tolerable, yet efficacious,
alternative to current pharmacological armamentarium.
Nonetheless, it must be remarked that the R-AMSTAR
grading system is relative to the set at review, which does
not necessarily mean absolute high quality of reporting for a
given review out of the set at overview. This further solicits
additional primary research studies (namely, RCTs to fill
the gap of publication bias and allow meta-analysis of the
evidence), as well as the need for higher quality of reporting
of the forthcoming reviews (especially regarding the details
documenting research protocols procedures and the biases
encountered in the assessment of primary research, namely,
publication and sponsorship bias, to this end). On the other
side, the trend of publication of reviews about lurasidone
confirms the clinicians’ interest about this compound, even
in the treatment of BD, as depicted in Figure 4.
Specifically, despite growing body of literature detailing
the efficacy and tolerability of lurasidone, a complementary
body of literature documenting its efficacy for the treatment
of BD-I is comparatively less than the one concerning
other SGAs, essentially due to the short time since initial
approval (subsequently extended beyond the sole treatment
of schizophrenia). This later issue may also concur the
explanation why most of the “systematic” reviews on the
matter essentially focused on the pharmacodynamics and/or
pharmacokinetics of the drug rather than on RCT studies
[90]. In this regard, it is alsoworth noticing that the upcoming
clinical trials should ideally investigate the impact of cur-
rent and/or lifetime mixed features as primary outcomes.
Similarly, greater attention and stratification of the reported
results by upcoming RCTs should focus on psychotic features
and (emerging) suicidality, which would on turn demand
for extended longitudinal follow-up, including flexible-dose
regimen arms, to better investigate medication adherence
to lurasidone across varying dosing patterns [91]. This is
particularly true considering that BD and mood disorders
in general should be better evaluated from an extended
longitudinal perspective, as originally postulated by Emil
Kraepelin for “manic-depressive illness” [17, 18].
4.1. Study Limitations. Sponsorship, publication biases, and
shortage of grey literature on the matter may have limited
the availability of negative result trials documented either
by primary or secondary research reports. Though assessed
for methodological quality, additional biases inherent to the
original field trials (e.g., selection bias) may have hampered
the generalizability of the overall conclusions drawn herein.
Both the psychometric properties and scoring guidance of
the adopted R-AMSTAR may still lack in terms of validity
(measurement bias). In addition,most of the included studies
were written in the English language (potential language
bias). English-written papers are likely to be published more
rapidly (time-lag bias) and cited more often (citation bias).
This is compelling for novel compounds as the mentioned
publication bias may represent an issue especially in the
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Figure 4: Number of studies and quality as assessed by the “Revised-A measurement tool to assess the methodological quality of systematic
reviews” (R-AMSTAR) [44] total score for systematic reviews, per year. Note: 2016 records could be updated till late October.
absence of negative results reports and in the presence of
sponsored RCTs only to date.
4.2. Lurasidone in the Treatment of Bipolar Depression: Major
Clinical Implications andRecommendations for FutureClinical
Studies to “Meet the Unmet Needs”. The Program to Eval-
uate the Antidepressant Impact of Lurasidone (PREVAIL)
planned in 2009 by lurasidone manufacturer with the goal to
evaluate the efficacy and tolerability of lurasidone as both a
monotherapy and as an adjunctive therapy in adult patients
purportedly excluded psychotic cases of depression associ-
ated with BD-I [59]. While this later strategy was intended
to ensure improvement of depressive ratings due to specific
antidepressant efficacy of lurasidone rather than effect of the
psychotic features (excluded per protocol), concerns regard-
ing the chance of Berkson’s bias for subsequent efficacy results
are documented in the developed acute and open-phase
extension trials which lead to FDA approval. Thus, future
trials should ideally include representative samples of BD-I
depression with concurrent psychotic features too [92] and
stratify results accordingly, as alternative post hoc analyses
(e.g., [59, 67, 93]) from the same original RCTs adopted
stratification of reporting of the results either for patients
aged 55 years or older (Dols, et al.), history of treatment
resistant depression [29, 30] and/or mixed features [94].
Moreover, lurasidone loose D2 postsynaptic occupancy (fast
dissociation time) compared to alternative antipsychotics
may represent itself a plus in the management of psychotic
features associated with core mood disturbances as well [95].
Interest about lurasidone in the treatment of depression
with mixed features, even when associated with sub- [94] or
full-threshold bipolarity rather than major depression [96,
97], is also a matter of vivid clinical debate, although the
actual differential diagnostic role of “irritability” remains an
argument of debate against current DSM-5 approach [10, 84,
98].
Despite the need for the future assessment of the above
specific features and/or special populations, as outlined by
most of the reviewed systematic reviews and additional
commentaries on the matter, overall evidence of efficacy of
lurasidone as (acute antidepressant) monotherapy for adult
patients with BD has an additional translational value [20,
21], as many individuals with BD are treated with polyphar-
macy even in circumstances where the most adequate initial
approach would be monotherapy [17, 18], with potential
detrimental effects on overall treatment adherence [99, 100].
Additional outcomes in cognitive data analyses are
nonetheless awaited to determine if there is a key differ-
ence between lurasidone and other SGAs with respect to
efficacy [63, 101], stating both the core relevance of cognitive
symptoms of bipolar depression [102, 103] and the recom-
mendations for future trials to account for personalized or
individualized medicine (including biomarkers) even in BD
[104].
Among others, clinical concerns raised upon overview
of qualitative and quantitative evidence of lurasidone in BD
would regard the need for inclusion of active compound
alternative arms in future RCTs (e.g., fixed versus standard
dose head-to-head comparisons of lurasidone against OFC,
quetiapine, or alternative SGAs). Once again, long-term
maintenance double-blind (extension) studies are likewise
warranted [105]. Ideally, independent controlled trials would
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test whether any significant statistical and/or clinical thresh-
old effect would be detected in RCTs directly comparing
mono- versus adjunctive therapy regimens (regardless the
presence of a third arm including placebo).
The need for additional information on special popu-
lations and/or clinical presentations is likewise compelling,
especially considering that trials based on the Diagnostic
and Statistical Manual Fifth Edition (DSM-5) [106] specifiers
of mixed features or rapid-cycling specifier are missing (or
yet to be disclosed to the public at writing time), as well as
additional information about otherwise relevant course and
specifiers not (yet?) accounted by the DSM, including, but
not limited to, predominant polarity index [53], stratification
of results and specific analyses about gender, and differential
comorbidity profile, which may in turn play a differential
impact on both efficacy and tolerability outcome measures
as recently stressed out by comprehensive evidence-based
guidelines for treating BD [107].
4.3. Concluding Remarks and Future Perspectives. Overall,
the present overview outlined concordant unmet needs and
recommendations about the use and potential future avenues
of lurasidone in the treatment of bipolar depression in adults,
with a special emphasis towards its therapeutic potential for
cases of treatment resistant and/or mixed features of bipolar
depression. In conclusion, lurasidone holds clinical potential
as a novel, efficacious pharmacological treatment for bipolar
depression [66]. However, the present overview confirms that
current data on its use in the BD-I population are limited by
publication bias and standardization of trial studies design.
To this end, while its monotherapy and once a day admin-
istration coupled with relatively favorable metabolic and
cognitive profile indeed represent an intriguing opportunity
for policy-makers and budget holders as well the prescribing
clinicians and the patients, more extensive research, both
longer in duration and independently conducted, is needed.
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